other material
confidence high
sentiment positive
materiality 0.85
Fortress Biotech subsidiary Cyprium closes PRV sale for $205M; Fortress expects over $100M
Fortress Biotech, Inc.
- Cyprium sold Rare Pediatric Disease Priority Review Voucher for $205M gross proceeds.
- Fortress (80.4% owner) expects over $100M from dividends and intercompany agreements.
- PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on Jan 12, 2026.
- Cyprium redeemed all outstanding 9.375% Perpetual Preferred Stock in connection with sale.
- Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to ~$128M in milestones.